Current Studies
Explore our current studies
For more information email: [email protected]
EZEF Study
Are you an adult with elevated lipoprotein(a) (Lp(a)) levels?
Join the ACCLAIM-Lp(a) study that assesses if lowering Lp(a) using lepodisiran can decrease the risk of serious cardiovascular complications. This is a Phase III Clinical Trial and on a large-scale, late-stage study evaluating whether the investigational medication lepodisiran can reduce major heart and vascular events in people with high Lp(a).
You might be a good fit for our study if you:
- Are an adult with elevated lipoprotein(a) (Lp(a)) levels, and
- If you are considered at risk for your first heart or blood vessel event (like a heart attack or stroke).
Elevated Lp(a) is a genetic risk factor for heart and artery diseases, even when other risk factors like cholesterol are under control. This study explores whether targeting Lp(a) with investigational medication can help reduce that risk, making it a potential step toward more personalized heart care.
- Main Focus: If your Lp(a) is high and you meet other health criteria, researchers will explain how the study works.
- Who Can Join: Adults 55 years old and older with certain risk factors (current tabacco use, high blood pressure, kidney disease, high cholesterol or diabetes, etc)
- Compensation: Up to $1300 or more if you qualify plus $56 for the initial blood test.
What’s Next If You’re Interested? Call our study team to arrange a quick blood test to see if you qualify.
AZURE Study
Can investigational medication reduce cardiovascular events?
Join the AZURE Study to determine whether the investigational medication can reduce the risk of serious cardiovascular events in people with ASCVD or high cardiovascular risk. This is a Phase III Clinical Trial, a late-stage study with many participants to confirm effectiveness and gather safety information of an investigational medication.
You might be a good fit for our study if you:
- Are an adult (18+) with established ASCVD, such as a previous heart attack, angina, stroke, or peripheral artery disease (PAD), OR
- Are at high risk for your first cardiovascular event due to conditions such as diabetes, high blood pressure, current smoking, chronic kidney disease, or being overweight.
If you’re living with ASCVD or at elevated risk for significant cardiovascular events, this study offers access to a new investigational treatment in a carefully monitored environment. Your participation could help improve future care for people at risk of serious heart and blood vessel conditions—and you’ll receive close medical attention throughout the process.
- Main Focus: Determine if investigational medication can reduce major cardiovascular events
- Who Can Join: Adults with ASCVD or high cardiovascular risk
- Compensation: Up to $1600 or more if you qualify.
What’s Next If You’re Interested? Call our study team to learn more and schedule a screening
PSK03 Study
Evaluate immune response to new pneumococcal vaccine.
Join the PSK03 Study to evaluate safety and immune response to the 21-valent vaccine, which may protect against more strains of pneumococcal disease.
Your child might be a good fit for our study if they:
- Are healthy and between 2 months and 15 months old
- Have not received more than one pneumococcal vaccine dose
Your child may receive a vaccine that could offer broader protection against pneumococcal disease, with regular medical check-ups at no cost. You will contribute to research that may improve future childhood vaccines.
- Main Focus: Evaluate safety and immune response to new pneumococcal vaccine
- Who Can Join: Healthy children ages 2–15 months with limited prior pneumococcal vaccination
- Compensation: $1000 if you qualify.
What’s Next If You’re Interested? Contact our study team to learn more and schedule a screening visit.
GSK Varicella Study
Your child might be a good fit for our study.
Join the GSK Varicella Study to determine if the investigational vaccine produces consistent immune responses across batches and is as safe and effective as Varivax®. Children will be randomly assigned to receive either the investigational varicella vaccine or the licensed Varivax® vaccine.
Your child might be a good fit for our study if they:
- Are healthy and between 12–15 months old
- Have not yet received a chickenpox (varicella) vaccine
Your child will receive a chickenpox vaccine as part of the study and be closely monitored by healthcare professionals. You will contribute to research that could help protect more children from chickenpox in the future.
- Main Focus: Compare immune response and safety between investigational vaccine and Varivax®
- Who Can Join: Healthy children ages 12–15 months who have not had a varicella vaccine
- Compensation: $500 if you qualify (Study only has 2 visits)
What’s Next If You’re Interested? Call our study team to learn more and schedule a screening visit.
dal-GenE-2 Study
Lower the risk of heart attacks in this study.
Join the dal-GenE-2 Study to explore a precision-medicine approach to treatment tailored to genetic makeup. This Phase III Clinical Trial will evaluate whether an investigational medication can help lower the risk of future heart attacks in people who’ve recently had ACS and carry this genetic profile.
You might be a good fit for our study if you:
- Are aged 45 or older, AND
- Have had a heart attack (Acute Coronary Syndrome) within the past 90 days, AND
- Have the AA genotype at variant rs1967309 in the ADCY9 gene (determined by a simple blood test).
- Main Focus: Reduce future heart attack risk in genetically susceptible individuals
- Who Can Join: Adults 45+ with ACS in past 90 days and specific genetic profile (AA genotype at rs1967309)
- Genetic Factor: Treatment targeted to genetic risk
- Compensation: $1000 or more if you qualify, plus $100 for the initial blood test.
What’s Next If You’re Interested? Call our study team to arrange a quick blood test to see if you qualify.
Merck MK-4482 COVID-19
Reduce the risk of COVID progression and hospitalization.
Join the Merck MK-4482 COVID-19 Study to determine if this investigational medication can safely and effectively reduce the risk of hospitalization or severe illness in high-risk adults with COVID.
You might be a good fit for our study if you:
- Are 18 years or older
- Have recently tested positive for COVID
- Are not hospitalized but are at higher risk for severe illness due to chronic conditions, weakened immune system, or older age
It’s important to receive access to an investigational antiviral treatment under close medical supervision. Help advance research to find better treatments for COVID while potentially protecting yourself from worsening illness.
- Main Focus: Reduce the risk of COVID progression and hospitalization
- Who Can Join: Adults 18+ with confirmed COVID and high risk for complications
- Compensation: $1100 if you qualify plus $100 for the initial screening.
What’s Next If You’re Interested? Call our study team to learn more and enroll as soon as possible after diagnosis.
DFU Study
Improve healing rates of diabetic foot ulcers.
Join the DFU Study to assess whether adding the amnion membrane allograft to standard care can improve healing rates for diabetic foot ulcers. You may receive a promising new treatment designed to help wounds heal faster, with regular monitoring from a dedicated medical team. Help advance care for others living with diabetic foot ulcers.
You might be a good fit for our study if you:
- Are 18 years or older
- Have diabetes
- Have a foot ulcer (less than 1 year old) that has not healed after standard treatment
- Main Focus: Improve healing rates of diabetic foot ulcers
- Who Can Join: Adults 18+ with diabetes and a non-healing foot ulcer
- Compensation: $2100 if you qualify.
What’s Next If You’re Interested? Contact our study team to learn more and schedule a screening visit.